Economic Overview
Life sciences employment across the Bay Area, according to Lightcast, ended the third quarter of 2026 at 104,400 positions, with some of the largest employers in the region being BioMarin Pharmaceutical, Amgen, and Gilead Sciences. The Bay Area continues to be the top U.S. market in employment with Boston (101,900) and New York (87,000) following. Life sciences in the local region partially thrives from funding to universities from the National Institutes of Health (NIH); in the third quarter, Stanford ranked eighth while UCSF took the second spot, based on dollars awarded nationally.
Venture capital funding into Bay Area life sciences companies in the third quarter came in at $2.1 billion, according to Pitchbook. During that period, Bay-Area headquartered companies received 28.0% of the total U.S. funding. The largest deals in the region went to San Francisco-based Chai Discovery at $400.0 million and South San Francisco-based Encoded at $275.0 million.
Supply & Demand: Rising Vacancy in the East Bay
The overall vacancy rate at the end of the third quarter of 2026 was 28.5%, down 20 basis points (bps) from 28.7% in the previous quarter and down 60 bps from 29.1% one year ago. Direct vacancy stayed relatively flat around 11.5 million square feet (msf). Sublease vacancy was consistent quarter-over-quarter as well at 2.5 msf. East Bay Oakland vacancy increased the most year-over-year, up 230 bps or 255,104 square feet (sf) from the same quarter last year, largely due to the delivery of new construction projects that completed in 2025. Additional consolidations also contributed to vacancy over the last 18 months.
There was 828,511 sf of total leasing activity (new leases and renewals) for the third quarter, an increase from the 748,556 sf in the second quarter, and up from 783,364 sf during the same period last year. New leases made up 75.4% or 624,859 sf of the activity, while renewals made up the rest at 24.6% or 203,652 sf. New leases with Lilly Gateway Labs (South San Francisco) and Structure Therapeutics (South San Francisco) contributed significantly to activity this quarter.
Supply: Eight Large-Scale Projects Completed in 2025 & 2026
There were eight ground-up developments, all speculative and totaling approximately 2.0 msf, completed since the beginning of 2025. These included Avia Labs (315,000 sf) in Millbrae, SPUR Phase I (330,350 sf) in South San Francisco, and The Landing (503,500 sf) in Burlingame. Along with those were 1030 Brittan Ave (108,134 sf) in San Carlos which was preleased to MBC Biolabs in 2022, Portal 405 (240,000 sf) in San Carlos, Menlo Park Labs (268,468 sf), and 200 Twin Dolphin (234,000 sf) in Redwood Shores. Finally, the last project that completed construction was ELCO Yards – The Shop in Redwood City, totaling 225,878 sf.
Conversions were more active in the Bay Area in the third quarter with roughly 336,433 sf in the pipeline. Projects under renovation are 2400-2470 Charleston Road (108,474 sf) in Mountain View, Island Parkway (179,172 sf) in Redwood Shores, and 901 California Avenue (54,800 sf) in Palo Alto.
Pricing: Rents Remain Muted
The overall average asking rate for Bay Area life sciences space closed out the third quarter at $5.53 per square foot (psf) on a monthly triple net basis, a decrease from $5.93 psf one year ago.
Overall average asking rates have been steadily decreasing in in the Santa Clara County and San Mateo County markets with the former having the largest change from $4.58 psf in the second quarter of 2026 to $4.32 psf in the third quarter. San Francisco County recorded a quarterly increase to its average asking rates due to several higher-end spaces that came to market including 1700 Owens Street.
Tenants in the Market:
There were 54 life sciences tenants in the market throughout the Bay Area at the close of the third quarter of 2026, totaling 2.4 msf with an average requirement size of 44,676 sf. San Mateo County counted the most tenant requirements at 35, while also averaging the highest requirement size at 50,929 sf.